The Scientist

» cancer immunotherapy

Most Recent

More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 

0 Comments

image: Gilead to Pay Nearly $12B for CAR T-Cell Company

Gilead to Pay Nearly $12B for CAR T-Cell Company

By Jef Akst | August 28, 2017

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

0 Comments

image: The Cancer Genes Needed for Immunotherapy Response

The Cancer Genes Needed for Immunotherapy Response

By Anna Azvolinsky | August 7, 2017

Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.  

0 Comments

In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 

1 Comment

image: Gene Mutations Foretell Immunotherapy Response

Gene Mutations Foretell Immunotherapy Response

By Aggie Mika | June 12, 2017

A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes. 

0 Comments

image: Hitting It Out of the Park

Hitting It Out of the Park

By Mary Beth Aberlin | April 1, 2017

Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.

0 Comments

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By Catherine Offord | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

image: Tasmanian Devil Cancer Immunotherapy

Tasmanian Devil Cancer Immunotherapy

By Bob Grant | March 13, 2017

Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.

0 Comments

image: Kite’s CAR T-Cell Therapy Success

Kite’s CAR T-Cell Therapy Success

By Jef Akst | March 1, 2017

More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.

0 Comments

image: FDA Approves Bladder Cancer Immunotherapy

FDA Approves Bladder Cancer Immunotherapy

By Jef Akst | May 23, 2016

The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.

0 Comments

Popular Now

  1. DNA Robots Target Cancer
    Daily News DNA Robots Target Cancer

    Researchers use DNA origami to generate tiny mechanical devices that deliver a drug that cuts off the blood supply to tumors in mice.

  2. Love in the Scientific Literature
    News Analysis Love in the Scientific Literature

    There are countless ways for scientists to say, “I love you.” Naming a slime-mold beetle after your wife (and another after your ex-wife) is, apparently, one of them.  

  3. Stem Cell Vaccine Protects Mice From Cancer
  4. Gene Expression Overlaps Among Psychiatric Disorders
AAAS